Emergent BioSolutions Inc. (EBS) — Financial statements
Income statement, balance sheet, and cash flow for Emergent BioSolutions Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 743↓28.8% | 1,044↓0.5% | 1,049↓6.1% | 1,118↓37.0% | 1,774 | |
| Cost of Revenue | 392↓41.3% | 668↓3.1% | 689↑7.0% | 645↓34.3% | 980 | |
| Gross Profit | 351↓6.6% | 375↑4.3% | 360↓23.9% | 473↓40.4% | 793 | |
| Operating Expenses | ||||||
| R&D Expenses | 54↓23.9% | 71↓36.5% | 111↓40.8% | 188↓19.9% | 235 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 187↓37.5% | 299↓16.3% | 357↑5.1% | 340↓2.6% | 349 | |
| Other Expenses | 0.00↓100.0% | 115↓81.4% | 618↑436.7% | 115↑187.2% | -132 | |
| Operating Expenses | 240↓50.3% | 484↓55.4% | 1,086↑69.0% | 643↑42.3% | 452 | |
| Total Costs & Expenses | 633↓45.1% | 1,152↓35.1% | 1,776↑37.9% | 1,288↓10.1% | 1,432 | |
| Operating Results | ||||||
| Operating Income | 110↑201.4% | -109↑85.0% | -726↓327.3% | -170↓149.8% | 341 | |
| Depreciation & Amortization | 98↓6.9% | 106↓12.8% | 121↓3.1% | 125↑5.8% | 118 | |
| EBITDA | 209↑290.4% | 53↑213.6% | -47↓399.4% | 16↓96.9% | 504 | |
| EBIT | 110↑311.1% | -52↑68.9% | -168↓53.8% | -109↓128.3% | 386 | |
| Interest & Other Income | ||||||
| Net Interest Income | -59↑16.5% | -71↑19.2% | -88↓135.7% | -37↓8.1% | -35 | |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 59↓16.5% | 71↓19.2% | 88↑135.7% | 37↑8.1% | 35 | |
| Non-Operating Income | 0.00↑100.0% | -57↑89.9% | -558↓819.8% | -61↓36.1% | -45 | |
| Other Income / Expenses | -27↑19.9% | -34↓612.5% | -5↑90.2% | -49↓28.3% | -38 | |
| Income Before Tax | 83↑157.9% | -143↑80.5% | -731↓233.9% | -219↓172.2% | 303 | |
| Income Tax Expense | 30↓36.7% | 48↑62.8% | 29↑495.9% | -7↓108.8% | 84 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 53↑127.6% | -191↑74.9% | -761↓259.4% | -212↓196.4% | 220 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 53↑127.6% | -191↑74.9% | -761↓259.4% | -212↓196.4% | 220 | |
| Bottom-Line Net Income | 53↑127.6% | -191↑74.9% | -761↓259.4% | -212↓196.4% | 220 | |
| EPS (Basic) | 0.98↑127.2% | -3.60↑75.8% | -14.85↓251.9% | -4.22↓202.9% | 4.10 | |
| EPS (Diluted) | 0.93↑125.8% | -3.60↑75.8% | -14.85↓251.9% | -4.22↓203.9% | 4.06 | |
| Weighted Average Shares | 54↑0.9% | 53↑3.5% | 51↑2.2% | 50↓6.4% | 54 | |
| Weighted Average Diluted Shares | 57↑7.0% | 53↑3.5% | 51↑2.2% | 50↓7.4% | 54 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.